SCHEMBL7879712

SCHEMBL7879712

CN(C(=N)N)C(=O)c1cc2ccc(OCCCN3CCCC3)cc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.55
HRH3 Q9Y5N1 5/20 0.50
PDGFRB P09619 2/20 0.48
PDGFRA P16234 1/20 0.48
DRD2 P14416 7/20 0.48
DRD3 P35462 5/20 0.48
MAOB P27338 2/20 0.45
CHEK2 O96017 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DRD4 P21917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7879688 0.95 FLT3 (0.60) FLT3PDGFRBPDGFRADRD2DRD3
Hydrochloric Acid SCHEMBL8628097 0.84 FLT3 (0.47) FLT3PDGFRBPDGFRADRD2DRD3
Hydrochloric Acid SCHEMBL7879743 0.84 FLT3 (0.47) FLT3PDGFRBPDGFRADRD2DRD3
SCHEMBL7881219 0.84 PDGFRB (0.56) FLT3HRH3PDGFRBPDGFRADRD2
SCHEMBL7877790 0.84 FLT3 (0.43) FLT3HRH3PDGFRBDRD2DRD3
SCHEMBL7879727 0.84 FLT3 (0.48) FLT3PDGFRBPDGFRADRD2DRD3
Hydrochloric Acid SCHEMBL7881410 0.83 SYK (0.48) FLT3PDGFRBPDGFRADRD2DRD3
SCHEMBL7877763 0.83 FLT3 (0.61) FLT3PDGFRBPDGFRADRD2DRD3
SCHEMBL7873204 0.82 HRH3 (0.42) FLT3HRH3DRD2DRD3CHEK2
SCHEMBL7880873 0.82 RXFP1 (0.43) FLT3HRH3DRD2DRD3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed